Tapering Heart Failure Medication in Patients With Heart Failure With Recovered Ejection Fraction; Open Label Prospective Random Trial
NCT: NCT06724653 ·
Status: RECRUITING ·
Phase: N/A
· Sponsor: Chungnam National University Hospital
· Started: 2025-03-06
· Est. Completion: 2027-11-26
Official Summary
Study start date is on Nov 27th 2024. A patient with an initial ejection fraction (EF) of less than 40%, whose follow-up shows an improvement to an EF of 50% or higher, along with the left ventricular end-diastolic diameter returning to the normal range and taking 3 more heart failure medication randomed to drug tapering group ( RAS blocker or beta blocker) or continuing medication group.
Study Design
- Study Type: INTERVENTIONAL
- Allocation: RANDOMIZED
- Model: PARALLEL
- Masking: SINGLE
- Enrollment: 150 participants
Interventions
- DRUG: RAS blocker tapering group — RAS blocker tapering out
- DRUG: Beta blocker tapering out — Beta blocker tapering out group
Primary Outcomes
- Heart failure relapse (From enrollment to the end of treatment at 18 months)
Trial Locations
- Jeonbuk national university hospital, Jeonju, Jeollabuk-do, South Korea
- Chungnam national university hospital, Daejeon, Republic of Korea, South Korea
More Heart Failure Trials
AI-generated analysis for educational purposes only. This is not medical advice. Discuss clinical trial participation with your doctor. Data sourced from ClinicalTrials.gov.